Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PRKAB2 | O43741 | 5/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 5/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 5/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 5/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 5/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 5/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | BAD | Q92934 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23146830 | 0.81 | KDM4E (0.49) | KDM4EPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23147026 | 0.78 | KDM4E (0.46) | KDM4EPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23146756 | 0.71 | GRIA2 (0.40) | HSD17B10GRIA2GRIA4ALDH1A1BCL2L1 | |
| SCHEMBL19063709 | 0.71 | BCL2L1 (0.44) | KDM4EPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1559220 | 0.70 | CLEC4M (0.49) | KDM4EALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL8601172 | 0.69 | CLCN2 (0.45) | KDM4EGRIA2GRIA4BCL2L1BAD | |
| SCHEMBL22188193 | 0.69 | GRIA2 (0.43) | KDM4EGRIA2GRIA4ALDH1A1 | |
| SCHEMBL23148035 | 0.69 | KDM4E (0.51) | KDM4EPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL23147673 | 0.69 | LMNA (0.46) | KDM4EHPGDHSD17B10ALDH1A1HTT | |
| SCHEMBL29812480 | 0.69 | KDM4E (0.51) | KDM4EPRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20220315579-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4034532-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE | Exelixis, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114787144-A | Pyridone compounds and methods for modulating protein kinases | 埃克塞里艾克西斯公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021062245-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE IN THE MODULATION OF A PROTEIN KINASE | EXELIXIS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | KDM4E 2816/4885PRKAB2 160/4885PRKAG1 162/4885 |
| US-20220315579-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, PLK2, MAP4K2 | KDM4E 2816/4885PRKAB2 160/4885PRKAG1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.